Liver Transplantation With Tregs at MGH
Public ClinicalTrials.gov record NCT03577431. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/II Drug Withdrawal Study of Alloantigen-Specific Tregs in Liver Transplantation (ITN073ST)
Study identification
- NCT ID
- NCT03577431
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 9 participants
Conditions and interventions
Conditions
Interventions
- arTreg-CSB Biological
- cyclophosphamide Drug
- everolimus Drug
- leukapheresis Procedure
- mesna Drug
Biological · Drug · Procedure
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 28, 2019
- Primary completion
- Feb 5, 2026
- Completion
- Apr 5, 2027
- Last update posted
- May 5, 2026
2019 – 2027
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Massachusetts General Hospital: Transplantation | Boston | Massachusetts | 02114 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Liver Transplant trials
Other public records listing Liver Transplant. Sorted by last update posted; newest first. Not a recommendation.
- NCT07778459: Expanding HOPE Liver Recruiting
- NCT07706166: Letermovir for R+ Study Not yet recruiting
- NCT01644903: Proteogenomic Monitoring and Assessment of Liver Transplant Recipients Recruiting
- NCT06280950: Expanding Liver Transplant Immunosuppression Minimization Via Everolimus Recruiting
- NCT07549503: Early Signals of the Transition From Immune Quiescence to Activation in the Liver Allograft Microenvironment and in the Circulation Not yet recruiting
- NCT06832189: EVR and EPO for Liver Transplant Tolerance Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03577431, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 5, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03577431 live on ClinicalTrials.gov.